Candidal infection is uncommon in acute oesophagitis: evidence from a non-selected DGH population

Mucosal candida infection of the lower oesophagus is unusual except in certain groups of patients who are either immuno-suppressed or who have other recognised causes of candidal infection.1 Invasive oesophageal candidiasis occurs most often in the immunosuppressed, occurring in 10–20% of patients with myeloproliferative disorders or leukaemia and in up to 74% of patients with AIDS, with an increased frequency of infection in patients with endocrine disorders such as hyperparathyroidism. Previous studies have shown that the incidence of candidial infection in 22 000 consecutive hospital admissions was 0.1% (27 cases), whereas it was found in less than 5% of a general population presenting with gastrointestinal complaints.2 It is important to exclude invasive candidiasis as this is a major risk factor in the development of candidal septicaemia, which can result as a direct effect of visceral wall complication. Crotations of oesophageal candidiasis also include oesophageal stenosis and perforation, which may occur in the acute phase of infection, and which can be life threatening. Less commonly, pseudodiverticulosis may also result.3

Candidal oesophagitis is caused most commonly by C. albicans, C. tropicalis, and C. krusei.4 The diagnosis of invasive candidiasis requires a combination of clinical suspicion and laboratory investigation. Difficulties in diagnosis arise where the clinical presentation is non-specific or serology produces false positive results because of vulvovaginal candidiasis. Oesophageal brushings are useful for identifying mucosal surface candidal colonisation but are poor at detecting fungal infection.5

Here we present the results of a retrospective review of 60 cases of acute oesophagitis, with reassessment for candida by D-PAS staining. Sixty consecutive oesophageal biopsies coded on the laboratory computer SNOMED database as acute inflammation with or without ulceration were examined from the period 1997–1998. In our hospital few specimens are sent for mycological culture, and brush cytology is not performed for the diagnosis of candida.

Candidal staining—All cases had remaining tissue available. Additional sections were cut if no spare unstained sections were available and then the sections were stained with PAS-D. Sections were pretreated with fresh diastase solution (0.5 cm3 diastase in 50 ml deionised water) followed by treatment with periodic acid Schiff reagent and Carrazzi’s haematoxylin, with tapwater washes in between each stage. The original H&E sections were re-examined to identify the presence of squamous mucosa or gastric mucosa and the nature of inflammation present (acute or chronic). The sections were also re-examined for evidence of ulceration. The minimum criteria required for oesophageal ulceration was the presence of squamous mucosa with epithelial and inflammatory granulation tis-

Dihydrate biefringent calcium oxalate or Weddellite calcification

I read with interest the recent article by Singh and Theaker about calcium oxalate crystals within the secretions of ductal breast carcinoma in situ and would like to comment on the eponym “Weddellite calcification.”

The term Weddellite is used because originally calcium oxalate crystals were first described from the Weddell sea. The British explorer and seal hunter James Weddell (1787–1834) on the brigantine “Jane of Leith” (The Jane) of 160 tons, manned by 22 men, in search of fur seals, explored the southern seas (Falkland Islands, Cape Horn, and its neighbourhood). He discovered a “still sea, perfectly clear of field ice” in the furthest south position of 74° 1’S, which he named after his ship’s name, in 1832. It was a record sothing that would not be broken until Wilhelm Filchner passed it nearly 100 years later in 1911. Weddell gave the name of George IV to this sea, but the name was abandoned when in 1890 it was proposed the sea be renamed after its discoverer.

Weddell published a book of the trip called A Voyage Towards the South Pole. This book is interesting not only as a record of what was done there, but for the adventure and long after, the highest southern latitude reached, but also because he gave an account of the South Shetlands and South Orkney Islands, which he had discovered on a previous voyage.

Weddell also discovered the non-migratory earless seal (Weddell seal, Leptonychotes weddelli). This marine mammal grows to about three metres in length and about 400 kg in weight and is found around the south pole near the coast of Antarctica.

Little is known about Weddell’s life. He was born on 24 August 1787 in Ostend, a son of a working upholsterer, a native of Lanarkshire, who had settled in Leith dockyard. He read widely on the subject of seamen and navigation and rendered himself a capable and efficient navigator. He died unmarried in London in relative poverty on 9 September 1834 at the age of 47,

1 Wilcox CM, Karowe MW. Esophageal infections: etiology, diagnosis and management. Esophagus Gastric Du 1994;2:188–200
3 Hamilton SR. Esophagitis. In: Ming SC, Gold-
4 Jones JM. Laboratory diagnosis of invasive can-
5 Geisinger KR. Endoscopic biopsies and cyto-
logic brushings of the esophagus are diagnosti-

L J BALDWIN
Department of Pathology, Queen Alexandra Hospital, Cosham, Portsmouth PO6 3LY, UK
Although the purpose of Weddell's trip was not discovered, his name has been retained by three eponyms: the Weddell seal, the Weddell sea, and Weddelite (calcium oxalate).

CARLOS ORTIZ-HIDALGO
Department of Pathology, The American British Condubay Hospital, Star 136 Eq. Observatorio, Mexico City 01120, Mexico


The risk of infection transmission by blood transfusion in England

The review by Soldan and Barbara on the risks of infection transmission by blood transfusion is an interesting and comprehensive article. However, there is little reference of prion disease and in particular new variant Creutzfeldt-Jacob disease (nvCJD) and the recently recommended control measures for blood donated in the United Kingdom. The only mention is in the last paragraph where they state “whether prion disease can be transmitted by transfusion is currently uncertain.”

From 1995 to the end of March 1999, 40 cases of nvCJD had been reported in the United Kingdom, and it is currently not known how many people may be incubating it asymptptomatically. A recent working party report considers that the distribution of infectivity of nvCJD may be different from that of other forms of CJD, as in the former there may be more involvement of lymphoreticular tissues, possibly involving circulating lymphocytes. Evidence of nvCJD has previously been found in human tonsillar tissue.

In Britain donated blood supplies are to be treated to reduce the risk of patients being infected with nvCJD because of the theoretical risk that it could be transmitted by white blood cells. Plasma which is used to manufacture plasma products—for example, as used in haemophilia—is currently obtained from outside Britain. Also from November 1999 all cellular blood products will undergo leucodepletion, a method which removes up to 95% of white blood cells.

Hopefully, further research will resolve these uncertainties about the infectivity of blood products and allow an accurate determination of risk.

S DAWSON
Public Health Laboratory, Gloucestershire Royal Hospital, Gloucester GL1 3NN, UK

Authors’ response

We agree with the author of this letter that more comment about nvCJD and the adoption of measures to try to control its transmission by blood donated in the United Kingdom is warranted. The situation with regard to nvCJD, as described by Dr Dawson, was evolving during and since the time we wrote our review, and we welcome its addition to the record in this manner.

K SOLDAN
J BARBARA
PHLS, Colindale Avenue, London NW9, UK

An assessment of the artefacts introduced by mounting two parallel sections from each histological level of cervical punch biopsies.

A previous study that compared different methods of orienting cervical biopsies has been extended to determine the optimal method of mounting the sections, cut from these biopsies, on the slide to ensure that they are clearly visible for histological examination under the coverslip.

In this department six levels have traditionally been cut from each cervical biopsy, with two adjacent sections from each level being mounted on either side of the midline along the long axis of the slide. This practice places the sections in close proximity to the edge of the coverslip where they may not be protected if the coverslip moves medially or where they may become obscured if mountant is squeezed from between the slide and the coverslip, and becomes smeared over the edge of coverslip.

Two hundred routine cervical punch biopsies in which duplicate sections from each level were mounted on either side of the midline were assessed prospectively up to July 1999. They were compared with 47 biopsies, in which only one section was mounted at each level. At least one section was covered (62.5%) or obscured (53.5%) by mountant when duplicate sections were mounted from each level; the corresponding percentages when a single section was mounted at each level were 16.3% and 4.7%. The artefacts from a given level had been mounted, both sections were at least partly obscured by the mountant representing a potentially serious limitation in the diagnosis of such cases in 21% of cases.

Biomedical scientists should be discouraged from mounting parallel sections from histological levels because of the difficulty in ensuring that a section of adequate technical quality will be produced.

MARK K HEATLEY
Department of Pathology, The Royal Liverpool University Hospitals, Broadgreen and Liverpool, Fifth Floor, Duncan Buildings, Prescot Street, Liverpool L7 8XP, UK


Table 1 The number of sections not covered by the coverslip that were covered by balsam, and the number of levels where material was obscured by balasam; if two levels were mounted the level was only considered to be obscured if both sections were obscured.

<table>
<thead>
<tr>
<th>Number of sections</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of sections not protected by the coverslip.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Two sections/level</td>
<td>158</td>
<td>15</td>
<td>9</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>One section/level</td>
<td>42</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.016</td>
</tr>
<tr>
<td>Number of sections covered by mountant.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Two sections/level</td>
<td>75</td>
<td>31</td>
<td>41</td>
<td>24</td>
<td>14</td>
<td>5</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>One section/level</td>
<td>36</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
<td>0</td>
<td>0</td>
<td>0.0001</td>
</tr>
<tr>
<td>Number of levels obscured by mountant.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Two sections/level</td>
<td>93</td>
<td>33</td>
<td>41</td>
<td>15</td>
<td>12</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>One section/level</td>
<td>41</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.0001</td>
<td></td>
</tr>
</tbody>
</table>

Number of levels with both sections obscured by mountant. | | | | | | | | | | | | |
| Two sections/level | 158 | 36 | 3 | 2 | 1 | 0 | 0 | | | | | |
| One section/level | 43 | 0 | 0 | 0 | 0 | 0 | 0 | | | | 0.001 |

This book updates two related WHO publications, Basic Tests for Pharmaceutical Substances (1986) and Basic Tests for Pharmaceutical Dosage Forms (1991), and gives information on tests for a further 23 substances, 58 dosage forms, and four medicinal plant materials. The drugs/preparations listed are mainly from the WHO Model List of Essential Drugs (1997). Reagents, test solutions, and volumetric solutions not listed before are detailed in the present volume, although there is nothing on suppliers, and little on reagent stability, storage conditions, and so on. There is a cumulative index to the three books.

The tests are confined to a physical description of the material and simple colour and other reactions, and aim to facilitate identity testing of bulk supplies, for example when labelling is unclear, and to indicate whether gross degradation has occurred in certain substances. A lot of work has gone into this relatively short publication, as evidenced by the list (more than a page) of acknowledgements of individuals and collaborating centres. Is the book of interest to clinical/forensic laboratories? Probably not, except that some laboratories might find a few of the tests useful if asked to identify powders, and so on (see Flanagan RJ, et al. Basic analytical toxicology. Geneva: WHO, 1995). There are simpler ways of identifying tablets (for example, Ramsey JD, Woolley JM. TIC/2IC—a CD-ROM for the identification of tablets and capsules. The International Association of Forensic Toxicologists: Proceedings of the 35th Annual Meeting, Padova, 1997:174–82).

The tests are supplemented by a review of recent published non-WHO work on simple methods for identifying pharmaceuticals, including volumetric, spectrophotometric, and thin layer chromatographic (TLC) methods. It seems that more than 150 TLC procedures were developed by WHO collaborators in the early 1980s using some 40 different mobile phases, but this work was not published as it was thought necessary to try to reduce the number of mobile phases used. Publishing and updating books, data sheets, and so on is becoming easier as desk top and even electronic publishing become the norm. It remains to be seen how WHO will respond to this challenge—there is not even an email address for comments in the present volume.

R J FLANAGAN


The first edition of this book was published in 1990 with the subtitle A guide to the FAB classification. (The FAB group had by then published proposals for the classification of the acute leukemias, the myelodysplastic syndromes and the chronic lymphoid leukemias.) “This book is much more than an atlas,” quoted from a review of that edition, advertises this new volume from its back cover. How true. Much more than just a guide to the FAB classification too. It has been comprehensively revised and updated to include current immunophenotypic, cytogenetic, and molecular developments, and also consideration of scatterplot data from the new generation of automated counters. The book is both a comprehensive atlas of clearly reproduced photomicrographs of a whole range of common and rare leukaemic material, and an elegant and enthusiastically written treatise on leukaemia classification.

No classification of leukaemia can be perfect. The often competing criteria of easy and reproducible applicability, clinical relevance, and biological plausibility necessitate compromises. This work does not seek to champion or defend the FAB classifications, but explains them critically, and sets them in a contemporary context in the light of the newer technological developments. Cytogenetic and molecular discoveries have clarified many biological entities. Meanwhile, generations of careful morphologists, for whom Dr Bain is a contemporary standard bearer, have gone back to the microscopic appearances to find that much of the information was there for the want of looking. Thus we can predict from the preliminary appearances when we are going to find an 8:21 translocation or a 16 inversion, whether or not a Philadelphia negative case is going to be found to have a bcr rearrangement, and many more examples. For the clinical haematologist this is not only rapidly available free information, it is also fun, and there’s little enough of that around these days. Even the developing “Bugger the cytochemistry, what do the markers show?” school of haematology should be enticed back to their microscopes by this enthusiastic writing, and I commend this book unreservedly to all haematologists and trainees.

PETER CAREY

Practical Adult Cardiovascular Pathology Course

Royal Brompton Hospital, Imperial School of Medicine

6–7 March 2000

A “hands on” course approaching in detail the problems facing the diagnostic pathologist when dealing with cardiovascular pathology. Approaches to cardiac necropsy and sudden death will be emphasised. The course is aimed at trainees studying for the MRCPath.

Further details: Short Course Officer, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK; tel +44 (0)2073518172; fax +44 (0)2073518246; email: course@IC.ac.uk

British Society for Clinical Cytology

BSCCC Spring Tutorial: Cervical Cytology

Guy’s Hospital, London

7 April 2000

Lectures and workshops including “Invasive squamous cell carcinoma” (W Gray), “Borderline changes” (P Smith), and “Atrophic smears” (L Turnbull).

Further details: BSCC Office, EMI, Central Research Laboratories, Dawley Road, Hayes, Middx UB3 1HH, UK; tel +44 (0)181 6062511; fax +44 (0)181 6062565; email: lesley.couch@psilink.co.uk
An assessment of the artefacts introduced by mounting two parallel sections from each histological level of cervical punch biopsies.
Mark K Heatley

*J Clin Pathol* 2000 53: 85
doi: 10.1136/jcp.53.1.85-a

Updated information and services can be found at: [http://jcp.bmj.com/content/53/1/85.2](http://jcp.bmj.com/content/53/1/85.2)

These include:

**References**
This article cites 1 articles, 1 of which you can access for free at: [http://jcp.bmj.com/content/53/1/85.2#BIBL](http://jcp.bmj.com/content/53/1/85.2#BIBL)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)